Royal Biologics entered into a distribution agreement whereby Vilex will market and distribute Royal Biologics’ portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.
Royal’s product portfolio focuses on fully utilizing the potential of the patient’s own cells to maximize efficacy in bone graft and wound care procedures using Autologous and Live Cellular biologics. Current “Live” or “Viable” cell allografts use toxic preservatives that destroy or alter donor cells. Royal Biologics’s portfolio creates a unique ability to harness the potential within the patient’s own body and allows for safer, more cost-effective methods than existing industry standards. Royal’s ALC portfolio does not utilize toxic cyro-protectants or foreign toxic preservatives. As healthcare costs continue to rise, the industry is in need of novel and innovative biologic technologies. Royal’s ALC portfolio provides a best-in-class approach to treat fusion and soft tissue related injuries utilizing each patient’s own autologous cells. The partnership between Royal Biologics and Vilex will put these products at the forefront of lower extremity orthopedic surgeries.
“We are extremely excited to have Vilex, a leader in lower extremity orthopedic surgery, as our partner to distribute our Autologous and Live Cellular portfolio,” said Dan Schneider, Vice President of Sales at Royal Biologics. “Vilex has shown a great ability to produce high growth in a very competitive market and we are confident we will see similar results with our products now that they are available to Vilex’s network of over 50 distributors nationwide.”
Royal Biologics entered into a distribution agreement whereby Vilex will market and distribute Royal Biologics' portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.
Royal's product portfolio focuses on fully utilizing the potential of the patient's own cells to maximize efficacy in bone graft and wound...
Royal Biologics entered into a distribution agreement whereby Vilex will market and distribute Royal Biologics’ portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.
Royal’s product portfolio focuses on fully utilizing the potential of the patient’s own cells to maximize efficacy in bone graft and wound care procedures using Autologous and Live Cellular biologics. Current “Live” or “Viable” cell allografts use toxic preservatives that destroy or alter donor cells. Royal Biologics’s portfolio creates a unique ability to harness the potential within the patient’s own body and allows for safer, more cost-effective methods than existing industry standards. Royal’s ALC portfolio does not utilize toxic cyro-protectants or foreign toxic preservatives. As healthcare costs continue to rise, the industry is in need of novel and innovative biologic technologies. Royal’s ALC portfolio provides a best-in-class approach to treat fusion and soft tissue related injuries utilizing each patient’s own autologous cells. The partnership between Royal Biologics and Vilex will put these products at the forefront of lower extremity orthopedic surgeries.
“We are extremely excited to have Vilex, a leader in lower extremity orthopedic surgery, as our partner to distribute our Autologous and Live Cellular portfolio,” said Dan Schneider, Vice President of Sales at Royal Biologics. “Vilex has shown a great ability to produce high growth in a very competitive market and we are confident we will see similar results with our products now that they are available to Vilex’s network of over 50 distributors nationwide.”
Copy to clipboard 
